Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Cytori Therapeutics, Inc. Announces Resignation Of Effective November 1, 2014

October 21, 2014 – 5:00 am | Edit Post

The Board of Directors of Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that Lloyd H. Dean has tendered his resignation as a member of the Board, effective November 1, 2014. Mr. Dean has served as a director of the Company since 2010 and served as Chairman of the Companys Board of Directors from April 2011 until June 2013. Help employers find you! Check out all the

Inogen Announces Release To Market Of The At Home, An Innovative Home Oxygen Concentrator

October 21, 2014 – 5:00 am | Edit Post

GOLETA, Calif., Oct. 21, 2014 (GLOBE NEWSWIRE) — Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the…

Otonomy, Inc. Appoints Chief Commercial Officer

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 21, 2014 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the appointment of Anthony J. Yost…

MabVax Therapeutics, Inc. Nominates The Fully Human Antibody HuMab 5B1 As The Company’s Lead Clinical Development Candidate

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 21, 2014 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical stage oncology drug development company, announced today that it has formally nominated its HuMab 5B1 antibody as a clinical candidate for the diagnosis and treatment of pancreatic and colon cancer. The fully…

ResMed Inc. myAir??? Patient Engagement Platform Supports And Coaches Patients To Improve Compliance

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 21, 2014 /PRNewswire/ — ResMed (NYSE: RMD) today introduced myAir, a new personalized therapy management application for patients with sleep-disordered breathing. myAir equips patients with the information they need to resolve basic therapy issues so they can increase their comfort and stay compliant…

XPRIZE Announces Finalists for $2.25 Million <b>Nokia</b> Sensing XCHALLENGE

October 21, 2014 – 5:00 am | Edit Post

LOS ANGELES–(BUSINESS WIRE)–XPRIZE, the global leader in incentivized prize competition, today announced the 11 finalist teams selected for the $2.25M Nokia Sensing XCHALLENGE, a competition to develop breakthrough medical sensing technologies that will ultimately enable faster diagnoses and easier personal health monitoring. The final phase of the Nokia Sensing XCHALLENGE includes an online voting…

Celgene???s New Crohn???s Disease Drug Impressing Analysts

October 21, 2014 – 5:00 am | Edit Post

Simulations Plus Adds To Portfolio With Release Of Membraneplus

October 21, 2014 – 5:00 am | Edit Post

LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has expanded its product portfolio with the release of version 1.0 of its MembranePlus simulation software.Mr. John DiBella, vice president for marketing and sales of Simulations Plus, said…

ResMed Inc. Enhances U-Sleep Patient Management Platform With Action View For Easier Management By Exception

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 21, 2014 /PRNewswire/ –ResMed (NYSE:RMD) today announced a significant improvement to U-Sleep, its premium patient management platform, which allows home medical equipment providers (HMEs) to quickly and effectively manage patients with sleep apnea and respiratory conditions. U-Sleep’s new Action…

Breast Implant Maker, Sientra, Inc., Sets Terms For $75 Million IPO

October 21, 2014 – 5:00 am | Edit Post

Sientra, an early-stage producer of silicone gel breast implants, announced terms for its IPO on Monday. The Santa Barbara, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Sientra would command a fully diluted market value of $230 million.BusinessSientra received FDA approval in 2012 for…